---
document_datetime: 2025-11-23 07:44:03
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/quixidar.html
document_name: quixidar.html
version: success
processing_time: 0.2581891
conversion_datetime: 2025-12-29 22:56:42.693654
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Quixidar

[RSS](/en/individual-human-medicine.xml/65680)

##### Withdrawn

This medicine's authorisation has been withdrawn

fondaparinux sodium Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The Marketing Authorisation Holder (MAH) responsible for Quixidar, Glaxo Group Ltd notified the European Commission on 11 February 2008 of its decision to voluntarily withdraw the marketing authorisation for Quixidar for commercial reasons.

Quixidar was never marketed in the European Union. Arixtra is an identical product available in the European Union.

On 11 March 2008, the European Union issued a decision to withdraw the marketing authorisation for Quixidar. Pursuant to this decision, the European Public Assessment Report (EPAR) for Quixidar is updated to reflect that the marketing authorisation is no longer valid.

Quixidar : EPAR - Summary for the public

English (EN) (262.83 KB - PDF)

**First published:** 16/05/2008

**Last updated:** 16/05/2008

[View](/en/documents/overview/quixidar-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-865)

български (BG) (464.85 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/bg/documents/overview/quixidar-epar-summary-public_bg.pdf)

español (ES) (266.8 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/es/documents/overview/quixidar-epar-summary-public_es.pdf)

čeština (CS) (437.87 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/cs/documents/overview/quixidar-epar-summary-public_cs.pdf)

dansk (DA) (266.4 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/da/documents/overview/quixidar-epar-summary-public_da.pdf)

Deutsch (DE) (267.89 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/de/documents/overview/quixidar-epar-summary-public_de.pdf)

eesti keel (ET) (265.04 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/et/documents/overview/quixidar-epar-summary-public_et.pdf)

ελληνικά (EL) (529.57 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/el/documents/overview/quixidar-epar-summary-public_el.pdf)

français (FR) (267.58 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/fr/documents/overview/quixidar-epar-summary-public_fr.pdf)

italiano (IT) (266.93 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/it/documents/overview/quixidar-epar-summary-public_it.pdf)

latviešu valoda (LV) (442.53 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/lv/documents/overview/quixidar-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (412.92 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/lt/documents/overview/quixidar-epar-summary-public_lt.pdf)

magyar (HU) (428.27 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/hu/documents/overview/quixidar-epar-summary-public_hu.pdf)

Malti (MT) (437.92 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/mt/documents/overview/quixidar-epar-summary-public_mt.pdf)

Nederlands (NL) (266.63 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/nl/documents/overview/quixidar-epar-summary-public_nl.pdf)

polski (PL) (445.84 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/pl/documents/overview/quixidar-epar-summary-public_pl.pdf)

português (PT) (265.74 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/pt/documents/overview/quixidar-epar-summary-public_pt.pdf)

română (RO) (403.63 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/ro/documents/overview/quixidar-epar-summary-public_ro.pdf)

slovenčina (SK) (432.3 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/sk/documents/overview/quixidar-epar-summary-public_sk.pdf)

slovenščina (SL) (424.56 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/sl/documents/overview/quixidar-epar-summary-public_sl.pdf)

Suomi (FI) (265.92 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/fi/documents/overview/quixidar-epar-summary-public_fi.pdf)

svenska (SV) (265.76 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/sv/documents/overview/quixidar-epar-summary-public_sv.pdf)

## Product information

Quixidar : EPAR - Product Information

English (EN) (1.14 MB - PDF)

**First published:** 16/05/2008

**Last updated:** 16/05/2008

[View](/en/documents/product-information/quixidar-epar-product-information_en.pdf)

[Other languages (21)](#file-language-dropdown-451)

български (BG) (1.79 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/bg/documents/product-information/quixidar-epar-product-information_bg.pdf)

español (ES) (1.34 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/es/documents/product-information/quixidar-epar-product-information_es.pdf)

čeština (CS) (1.81 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/cs/documents/product-information/quixidar-epar-product-information_cs.pdf)

dansk (DA) (990.72 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/da/documents/product-information/quixidar-epar-product-information_da.pdf)

Deutsch (DE) (1.07 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/de/documents/product-information/quixidar-epar-product-information_de.pdf)

eesti keel (ET) (1.13 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/et/documents/product-information/quixidar-epar-product-information_et.pdf)

ελληνικά (EL) (1.81 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/el/documents/product-information/quixidar-epar-product-information_el.pdf)

français (FR) (1.21 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/fr/documents/product-information/quixidar-epar-product-information_fr.pdf)

italiano (IT) (1.52 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/it/documents/product-information/quixidar-epar-product-information_it.pdf)

latviešu valoda (LV) (1.57 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/lv/documents/product-information/quixidar-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.41 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/lt/documents/product-information/quixidar-epar-product-information_lt.pdf)

magyar (HU) (1.26 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/hu/documents/product-information/quixidar-epar-product-information_hu.pdf)

Malti (MT) (1.34 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/mt/documents/product-information/quixidar-epar-product-information_mt.pdf)

Nederlands (NL) (1.08 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/nl/documents/product-information/quixidar-epar-product-information_nl.pdf)

polski (PL) (1.57 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/pl/documents/product-information/quixidar-epar-product-information_pl.pdf)

português (PT) (1.05 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/pt/documents/product-information/quixidar-epar-product-information_pt.pdf)

română (RO) (1.48 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/ro/documents/product-information/quixidar-epar-product-information_ro.pdf)

slovenčina (SK) (1.36 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/sk/documents/product-information/quixidar-epar-product-information_sk.pdf)

slovenščina (SL) (1.29 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/sl/documents/product-information/quixidar-epar-product-information_sl.pdf)

Suomi (FI) (1.04 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/fi/documents/product-information/quixidar-epar-product-information_fi.pdf)

svenska (SV) (1.17 MB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/sv/documents/product-information/quixidar-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0034 24/10/2007

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Quixidar : EPAR - All Authorised presentations

English (EN) (471.82 KB - PDF)

**First published:** 16/05/2008

**Last updated:** 16/05/2008

[View](/en/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-390)

български (BG) (333.96 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/bg/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_bg.pdf)

español (ES) (234.07 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/es/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_es.pdf)

čeština (CS) (343.15 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/cs/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (233.44 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/da/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (232.34 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/de/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (233.05 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/et/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (313.32 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/el/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_el.pdf)

français (FR) (233.9 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/fr/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (233.23 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/it/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (341.29 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/lv/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (320.2 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/lt/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (338.67 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/hu/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (341.13 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/mt/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (232.88 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/nl/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_nl.pdf)

polski (PL) (343.76 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/pl/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_pl.pdf)

português (PT) (234.44 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/pt/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_pt.pdf)

română (RO) (317.36 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/ro/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (343.23 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/sk/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (293.41 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/sl/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (232.68 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/fi/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (234.58 KB - PDF)

**First published:**

16/05/2008

**Last updated:**

16/05/2008

[View](/sv/documents/all-authorised-presentations/quixidar-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Quixidar Active substance fondaparinux sodium International non-proprietary name (INN) or common name fondaparinux sodium Therapeutic area (MeSH)

- Venous Thrombosis
- Pulmonary Embolism
- Myocardial Infarction
- Angina, Unstable

Anatomical therapeutic chemical (ATC) code B01AX05

### Pharmacotherapeutic group

Antithrombotic agents

### Therapeutic indication

1.5 mg/0.3 ml and 2.5 mg/0.5 ml, solution for injection:

- Prevention of Venous Thromboembolic Events (VTE) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery.
- Prevention of Venous Thromboembolic Events (VTE) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery (see section 5.1).
- Prevention of Venous Thromboembolic Events (VTE) in medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infectious or inflammatory disease.

2.5 mg/0.5 ml, solution for injection:

- Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients for whom urgent (&lt; 120 mins) invasive management (PCI) is not indicated (see sections 4.4 and 5.1).
- Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.

5 mg/0.4 ml, 7.5 mg/0.6 ml and 10 mg/0.8 ml solution for injection:

- Treatment of acute Deep Vein Thrombosis (DVT) and treatment of acute Pulmonary Embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.

## Authorisation details

EMA product number EMEA/H/C/000404 Marketing authorisation holder

Glaxo Group Ltd.

Greenford Road Greenford, Middx UB6 0NN United Kingdom

Marketing authorisation issued 21/03/2002 Withdrawal of marketing authorisation 11/03/2008 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Quixidar : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (255.39 KB - PDF)

**First published:** 16/05/2008

**Last updated:** 16/05/2008

[View](/en/documents/procedural-steps-after/quixidar-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Quixidar-H-C-404-II-24 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (1.04 MB - PDF)

**First published:** 16/05/2008

**Last updated:** 16/05/2008

[View](/en/documents/scientific-discussion-variation/quixidar-h-c-404-ii-24-epar-scientific-discussion-variation_en.pdf)

Quixidar-H-C-404-II-10 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (521.91 KB - PDF)

**First published:** 16/05/2008

**Last updated:** 16/05/2008

[View](/en/documents/scientific-discussion-variation/quixidar-h-c-404-ii-10-epar-scientific-discussion-variation_en.pdf)

Quixidar-H-C-404-II-12 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (578.02 KB - PDF)

**First published:** 16/05/2008

**Last updated:** 16/05/2008

[View](/en/documents/scientific-discussion-variation/quixidar-h-c-404-ii-12-epar-scientific-discussion-variation_en.pdf)

Quixidar-H-C-404-X-25 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (347.01 KB - PDF)

**First published:** 16/05/2008

**Last updated:** 16/05/2008

[View](/en/documents/scientific-discussion-variation/quixidar-h-c-404-x-25-epar-scientific-discussion-variation_en.pdf)

## Initial marketing authorisation documents

Quixidar : EPAR - Scientific Discussion

English (EN) (1.27 MB - PDF)

**First published:** 16/05/2008

**Last updated:** 16/05/2008

[View](/en/documents/scientific-discussion/quixidar-epar-scientific-discussion_en.pdf)

Quixidar : EPAR - Procedural steps taken before authorisation

English (EN) (308.54 KB - PDF)

**First published:** 16/05/2008

**Last updated:** 16/05/2008

[View](/en/documents/procedural-steps/quixidar-epar-procedural-steps-taken-authorisation_en.pdf)

**This page was last updated on** 16/05/2008

## Share this page

[Back to top](#main-content)